AbbVie Inc. (ABBV)
NYSE: ABBV · Real-Time Price · USD
225.42
+2.35 (1.05%)
At close: Jun 9, 2026, 4:00 PM EDT
225.20
-0.22 (-0.10%)
After-hours: Jun 9, 2026, 7:53 PM EDT
AbbVie Employees
AbbVie had 57,000 employees as of December 31, 2025. The number of employees increased by 2,000 or 3.64% compared to the previous year.
Employees
57,000
Change (1Y)
2,000
Growth (1Y)
3.64%
Revenue / Employee
$1,102,088
Profits / Employee
$63,070
Market Cap
398.27B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 57,000 | 2,000 | 3.64% |
| Dec 31, 2024 | 55,000 | 5,000 | 10.00% |
| Jan 31, 2024 | 50,000 | 0 | - |
| Jan 31, 2023 | 50,000 | 0 | - |
| Jan 31, 2022 | 50,000 | 3,000 | 6.38% |
| Jan 31, 2021 | 47,000 | 17,000 | 56.67% |
| Jan 31, 2020 | 30,000 | 0 | - |
| Jan 31, 2019 | 30,000 | 1,000 | 3.45% |
| Jan 31, 2018 | 29,000 | -1,000 | -3.33% |
| Jan 31, 2017 | 30,000 | 2,000 | 7.14% |
| Jan 31, 2016 | 28,000 | 2,000 | 7.69% |
| Jan 31, 2015 | 26,000 | 1,000 | 4.00% |
| Jan 31, 2014 | 25,000 | 3,500 | 16.28% |
| Jan 31, 2013 | 21,500 | 0 | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Johnson & Johnson | 138,200 |
| AstraZeneca | 95,100 |
| Novartis AG | 75,267 |
| Merck & Co. | 75,000 |
| Pfizer | 75,000 |
| Sanofi | 74,846 |
| Novo Nordisk | 69,505 |
| Eli Lilly and Company | 50,000 |
ABBV News
- 11 hours ago - AbbVie Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 1 day ago - AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026 - PRNewsWire
- 6 days ago - British drug-cost watchdog recommends use of AbbVie's ovarian cancer therapy - Reuters
- 6 days ago - Getting Alzheimer's Drugs Into the Brain Is Hard. Now There's a New Trick. - Barrons
- 7 days ago - AbbVie to Present at the Goldman Sachs 47th Annual Global Healthcare Conference - PRNewsWire
- 11 days ago - AbbVie announces EC authorizes expanded label for Venclyxto - TheFly
- 11 days ago - AbbVie Announces European Commission Authorization of Expanded Label for VENCLYXTO® (venetoclax) to Include Additional Combinations in Previously Untreated Chronic Lymphocytic Leukemia - PRNewsWire
- 13 days ago - U.S. FDA Approves DECNUPAZTM (pivekimab sunirine-pvzy) for Treatment of Adult Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare and Aggressive Blood Cancer With Limited Treatment Options - PRNewsWire